Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 12 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma MOST POPULAR FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer May 25, 2021 A vision for the next decade of UK life sciences July 21, 2021 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors? July 27, 2021 Load more HOT NEWS When Prenatal DNA Tests Point to Cancer Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... NCI and FDA Address Common Concerns: A Win–Win for Making Progress... Rapid Genetic Test Could Help Guide Brain Cancer Surgery
